Acrivon Therapeutics, Inc. is a precision oncology therapeutics company with a unique proteomics-based patient selection platform. The company is focused on challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Acrivon aims to rapidly progress in-licensed clinical-stage assets and internally developed programs through accelerated registration trials. The company was founded in 2018 and is headquartered in the United States, with biomarker discovery efforts concentrated in its wholly-owned subsidiary in Lund, Sweden.
The latest investment of $130.00MPost-IPO Equity was received on April 9, 2024, led by prominent investors including RA Capital Management, Sands Capital Ventures, Acorn Bioventures, Perceptive Advisors, Paradigm BioCapital Advisors, and Surveyor Capital.
Acrivon Therapeutics' commitment to precision oncology and its robust platform make it an attractive prospect for venture capital firms seeking opportunities in the biotechnology, health care, and health and wellness industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $130.00M | 6 |
|
09 Apr 2024 |
| Series B | $100.00M | 4 |
|
11 Nov 2021 |
| Venture Round | $15.50M | - | 12 Feb 2021 |
No recent news or press coverage available for Acrivon Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
